Acanthosis nigricans - Revision history

Rossdonaldson1 at 16:14, 11 December 2024

2024-12-11T16:14:24Z

← Older revision		Revision as of 16:14, 11 December 2024
Line 6:		Line 6:
	*Associated with GI and GU malignancies, which may have concomitant weight loss		*Associated with GI and GU malignancies, which may have concomitant weight loss
	*Non malignant form may be associated with endocrine abnormalities, such as insulin resistance		*Non malignant form may be associated with endocrine abnormalities, such as insulin resistance

	~~{{Primary derm lesions names}}~~

	==Clinical Features==		==Clinical Features==

Rossdonaldson1: /* Evaluation */

2024-12-11T16:13:36Z

Evaluation

← Older revision		Revision as of 16:13, 11 December 2024
Line 20:		Line 20:

	==Evaluation==		==Evaluation==
			===Workup===

	===Diagnosis===		===Diagnosis===
	*Red flags for ''malignant'' acanthosis nigricans:		*Red flags for ''malignant'' acanthosis nigricans:

Rossdonaldson1 at 16:12, 11 December 2024

2024-12-11T16:12:08Z

← Older revision		Revision as of 16:12, 11 December 2024
Line 1:		Line 1:
	==Background==		==Background==
	{{Skin anatomy background images}}		{{Skin anatomy background images}}
	~~{{Primary derm lesions names}}~~
	*Multiple forms, but malignant acanthosis nigricans is most important		*Multiple forms, but malignant acanthosis nigricans is most important
	**Most commonly associated with [[colon cancer\|colonic adenocarcinoma]], gastric cancer, ovarian cancer		**Most commonly associated with [[colon cancer\|colonic adenocarcinoma]], gastric cancer, ovarian cancer
Line 7:		Line 6:
	*Associated with GI and GU malignancies, which may have concomitant weight loss		*Associated with GI and GU malignancies, which may have concomitant weight loss
	*Non malignant form may be associated with endocrine abnormalities, such as insulin resistance		*Non malignant form may be associated with endocrine abnormalities, such as insulin resistance

			{{Primary derm lesions names}}

	==Clinical Features==		==Clinical Features==

Rossdonaldson1: /* Background */

2024-12-11T16:10:31Z

Background

← Older revision		Revision as of 16:10, 11 December 2024
Line 1:		Line 1:
	==Background==		==Background==
			{{Skin anatomy background images}}
			{{Primary derm lesions names}}
	*Multiple forms, but malignant acanthosis nigricans is most important		*Multiple forms, but malignant acanthosis nigricans is most important
	**Most commonly associated with [[colon cancer\|colonic adenocarcinoma]], gastric cancer, ovarian cancer		**Most commonly associated with [[colon cancer\|colonic adenocarcinoma]], gastric cancer, ovarian cancer

Rossdonaldson1: /* References */

2023-03-29T20:46:02Z

References

← Older revision		Revision as of 20:46, 29 March 2023
Line 38:		Line 38:
	==References==		==References==
	<references/>		<references/>

			*Schwarzenberger K, Callen JP. Chapter 53: Dermatologic manifestations in patients with systemic disease. In: Bolognia JL,‎ Schaffer JV,‎ Cerroni L, eds. Dermatology. 4th ed. Philadelphia, PA: Elsevier; 2017:820.

	[[Category:Dermatology]]		[[Category:Dermatology]]

	Schwarzenberger K, Callen JP. Chapter 53: Dermatologic manifestations in patients with systemic disease. In: Bolognia JL,‎ Schaffer JV,‎ Cerroni L, eds. Dermatology. 4th ed. Philadelphia, PA: Elsevier; 2017:820.

Rossdonaldson1: /* See Also */

2023-03-29T20:44:56Z

Rossdonaldson1: /* Differential Diagnosis */

2023-03-29T20:43:39Z

Differential Diagnosis

← Older revision		Revision as of 20:43, 29 March 2023
Line 14:		Line 14:

	==Differential Diagnosis==		==Differential Diagnosis==
			{{DDX dark raised lesions}}

	==Evaluation==		==Evaluation==

Rossdonaldson1: /* See Also */

2023-03-29T20:43:12Z

Rossdonaldson1 at 20:42, 29 March 2023

2023-03-29T20:42:22Z

← Older revision		Revision as of 20:42, 29 March 2023
Line 1:		Line 1:
	==Background==		==Background==
	*Multiple forms, but malignant acanthosis nigricans is most important		*Multiple forms, but malignant acanthosis nigricans is most important
			**Most commonly associated with [[colon cancer\|colonic adenocarcinoma]], gastric cancer, ovarian cancer
			**Also associated with other dermal manifestations of internal cancers
	*Associated with GI and GU malignancies, which may have concomitant weight loss		*Associated with GI and GU malignancies, which may have concomitant weight loss
	*Non malignant form may be associated with endocrine abnormalities, such as insulin resistance		*Non malignant form may be associated with endocrine abnormalities, such as insulin resistance

	==Clinical Features==		==Clinical Features==
			[[File:malignant_acanthosis_nigricans_ovarian.png\|thumb\|Malignant acanthosis nigricans secondary to ovarian cancer]]
	*Hyperpigmented, velvety		*Hyperpigmented, velvety
	*Plaques		*Plaques
Line 10:		Line 13:
	*May have concurrent acrochordons, skin tags		*May have concurrent acrochordons, skin tags

	==~~Malignant Acanthosis Nigricans<ref>Miller JH et al. Acanthosis Nigricans Clinical Presentation. eMedicine. Dec 3, 2015. http://emedicine.medscape.com/article/1102488-clinical#showall.</ref>~~==		==Differential Diagnosis==
	~~[[File:malignant_acanthosis_nigricans_ovarian.png\|thumb\|Malignant acanthosis nigricans secondary to ovarian cancer]]~~
	*Associated with other dermal manifestations of internal cancers		==Evaluation==
	*Most commonly associated with [[colon cancer\|colonic adenocarcinoma]], gastric cancer, ovarian cancer		===Diagnosis===
	*Red flags:		*Red flags for ''malignant'' acanthosis nigricans:
	**Up to 50% ~~of malignant acanthosis nigricans have oral involvement~~		**Oral involvement (up to 50%)
	**Rapid appearance of lesions		**Rapid appearance of lesions
	**Extensive involvement		**Extensive involvement
Line 21:		Line 24:
	**Unexplained weight loss		**Unexplained weight loss
	**Lesions in atypical sites such as palms/soles, mucous membranes		**Lesions in atypical sites such as palms/soles, mucous membranes

	~~==Differential Diagnosis==~~

	~~==Evaluation==~~

	==Management==		==Management==

Rossdonaldson1: /* See Also */

2023-03-29T20:39:49Z

← Older revision		Revision as of 20:44, 29 March 2023
Line 34:		Line 34:
	==See Also==		==See Also==
	*[[Seborrheic keratosis]]		*[[Seborrheic keratosis]]
	*[[~~General approach to rashes~~]]		*[[Dark raised skin lesions]]

	==References==		==References==

← Older revision		Revision as of 20:43, 29 March 2023
Line 33:		Line 33:
	==See Also==		==See Also==
	*[[Seborrheic keratosis]]		*[[Seborrheic keratosis]]
			*[[General approach to rashes]]

	==References==		==References==

← Older revision		Revision as of 20:39, 29 March 2023
Line 29:		Line 29:

	==Disposition==		==Disposition==

			==External Links==

	==See Also==		==See Also==